#3 - Abbott Laboratories (NYSE:ABT)
As you can see, biopharmaceutical companies are some of the leading ESG companies due to the impact they have on public health. That’s also the case with our last biotech, Abbott Laboratories (NYSE:ABT) which has a 65.9% Net Impact Ratio according to Upright. Abbott stock is back on an upswing having climbed over 10% since reporting a strong double beat in its January earnings report.
Much of Abbott’s recent success is linked to strong demand for the company’s Covid-19 tests. That’s likely to level off even if, as expected, Covid-19 reaches an endemic stage. However, the company has a proven history of beating the S&P 500 over time. And on top of its stock price performance, investors are buying shares of a Dividend King. Abbott earned entry into this exclusive club by increasing its dividend in each of the last 50 years.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
More- Current Price
- $131.15
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 14 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $133.06 (1.5% Upside)
